F-star Therapeutics (F-star Therapeutics) Cash-to-Debt : 2.81 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. F-star Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2022 was 2.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, F-star Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for F-star Therapeutics's Cash-to-Debt or its related term are showing as below:

FSTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32 Med: 5.27 Max: 6.02
Current: 2.81

During the past 3 years, F-star Therapeutics's highest Cash to Debt Ratio was 6.02. The lowest was 0.32. And the median was 5.27.

FSTX's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.49 vs FSTX: 2.81

F-star Therapeutics Cash-to-Debt Historical Data

The historical data trend for F-star Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

F-star Therapeutics Cash-to-Debt Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Cash-to-Debt

0.32

5.86

5.94

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial							5.31	5.94	5.27	4.12	2.81

Competitive Comparison of F-star Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, F-star Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

F-star Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's Cash-to-Debt falls into.

F-star Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

F-star Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	78.549	/	(0.906	+	12.328)
	=	5.94

F-star Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	35.568	/	(2.141	+	10.537)
	=	2.81

F-star Therapeutics (NAS:FSTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

F-star Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116